Phaseline

Companies › Avidity Biosciences

Avidity Biosciences: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 2 Phase 3, 2 Phase 2; Neurology, Immunology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AOC 1044
antisense oligonucleotide for exon 44 skipping
DMDPhase 3Muscular Dystrophies; DMDApr 2027
AOC-1020 (Del-brax)
Antisense oligonucleotide targeting DUX4 mRNA
DUX4Phase 3Facioscapulohumeral Muscular DystrophyMay 2028
AOC 1020
Antisense oligonucleotide targeting DUX4 mRNA
DUX4Phase 2FSHDApr 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06244082AOC 1044Phase 2DMDNeurologyApr 2027
NCT07038200AOC-1020 (Del-brax)Phase 3Facioscapulohumeral Muscular DystrophyNeurologyMay 2028
NCT07587242AOC 1044Phase 3Muscular DystrophiesNeurologyMay 2029
NCT06547216AOC 1020Phase 2FSHDImmunologyApr 2030

Targets

DUX4 (2) DMD (1)

Companies with the same targets

Solid Biosciences NS Pharma Sarepta Therapeutics Dyne Therapeutics REGENXBIO Precision BioSciences Wave Life Sciences USA Belief BioMed (Beijing) Insmed Gene Therapy Nippon Shinyaku

Companies built like this

NS Pharma Nippon Shinyaku Sarepta Therapeutics Suven Life Sciences Shanghai Hutchison Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.